Adele Gulfo
In January 2025, Ms. Gulfo was appointed to the Board of Directors. She brings nearly three decades of executive leadership experience to the TYRA board, with a strong track record in developing and commercializing some of the world’s best-selling medicines at Pfizer, AstraZeneca, Viatris and Sumitomo Pharma. Most recently, Ms. Gulfo served as Chief Executive Officer, Biopharma Commercial Unit, for Sumitomo Pharma America, Inc. where she led the commercial and development portfolio for multiple therapeutic areas including oncology, rare disease, urology, CNS and Women's Health. Previously, Ms. Gulfo served as chief commercial and business development officer at Sumitovant Biopharma from 2020 to 2023. Previously, she served as chief commercial development officer at Roivant Sciences, where she was influential in the formation of Sumitovant and in preparations for the launches of key brands, including ORGOVYX® (prostate cancer), GEMTESA (overactive bladder), RETHYMIC (congenital athymia), and MYFEMBREE (women's health). Adele was the president and general manager of Pfizer's $12B+ U.S. primary care business unit, as well as country manager for Pfizer's U.S. Biopharma business, including specialty and oncology business units. Earlier in her career at Pfizer, Adele was instrumental in the development, launch, and commercial success of LIPITOR®, which became the world's best-selling medicine. Prior to Pfizer, Adele held vice president roles within AstraZeneca, including business development and innovation and commercial readiness, as well as the multi-billion-dollar cardiovascular business unit. She oversaw the launch of Crestor® and its growth into a $2 billion medicine.